AlzeCure Pharma AB (DE:AC6)
FRANKFURT:AC6
AC6 Stock Chart & Stats
€0.15
>-€0.01(-7.07%)
At close: 4:00 PM EST
€0.15
>-€0.01(-7.07%)
Day’s Range― - ―
52-Week Range€0.07 - €0.57
Previous CloseN/A
Volume0.00
Average Volume (3M)114.00
Market Cap
€50.27M
Enterprise Value€465.57M
Total Cash (Recent Filing)€50.34M
Total Debt (Recent Filing)€5.12M
Price to Earnings (P/E)―
Beta-1.00
Next Earnings
Aug 26, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.45
Shares Outstanding137,897,340
10 Day Avg. Volume0
30 Day Avg. Volume114
Financial Highlights & Ratios
PEG Ratio-1.94
Price to Book (P/B)6.11
Price to Sales (P/S)0.00
P/FCF Ratio-5.81
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.03
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage / Modest DebtThe company’s very low debt and 0.16 debt-to-equity ratio provide durable financial flexibility for an R&D-stage biotech. Low interest burden preserves cash for trials and partnering efforts, reducing near-term solvency risk and supporting the ability to withstand multi-year development cycles.
Focused CNS R&D PlatformsA focused R&D platform in CNS builds a structural competitive advantage: domain expertise and repeatable discovery processes increase probability of generating licensable candidates. Specialization attracts partners seeking CNS assets and supports multiple monetization pathways over the medium term.
Improving Cash-flow TrendAn improving free cash flow swing signals operational or financing progress that can extend runway. While still negative, a trend toward lower cash burn is durable if sustained, reducing frequency and size of equity raises and improving ability to fund key clinical milestones or partnering activities.
Bears Say
No Revenue And Widening Net LossAbsence of product revenue and a materially larger net loss undermine self-funding capacity and highlight the long path to commerciality. Persistent negative earnings weaken internal cash generation and increase structural reliance on external financing or partnerships to sustain R&D programs.
Consistent Negative Operating Cash FlowSustained negative operating cash flow indicates ongoing cash burn from R&D and operations. This durable drain constrains strategic optionality, forces periodic capital raises, and heightens execution risk if financing windows narrow during critical clinical development stages.
Equity Erosion And Dilution RiskSignificant decline in equity over several years reflects cumulative losses and raises the prospect of further dilution to fund operations. Persistent capital erosion can impair investor returns, reduce financial cushions, and make future financing more dilutive or costly for long-term shareholders.
AC6 FAQ
What was AlzeCure Pharma AB’s price range in the past 12 months?
AlzeCure Pharma AB lowest stock price was €0.07 and its highest was €0.57 in the past 12 months.
What is AlzeCure Pharma AB’s market cap?
AlzeCure Pharma AB’s market cap is €50.27M.
When is AlzeCure Pharma AB’s upcoming earnings report date?
AlzeCure Pharma AB’s upcoming earnings report date is Aug 26, 2026 which is in 69 days.
How were AlzeCure Pharma AB’s earnings last quarter?
AlzeCure Pharma AB released its earnings results on May 05, 2026. The company reported -€0.015 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.015.
Is AlzeCure Pharma AB overvalued?
According to Wall Street analysts AlzeCure Pharma AB’s price is currently Overvalued.
Does AlzeCure Pharma AB pay dividends?
AlzeCure Pharma AB does not currently pay dividends.
What is AlzeCure Pharma AB’s EPS estimate?
AlzeCure Pharma AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does AlzeCure Pharma AB have?
AlzeCure Pharma AB has 137,897,340 shares outstanding.
What happened to AlzeCure Pharma AB’s price movement after its last earnings report?
AlzeCure Pharma AB reported an EPS of -€0.015 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -6.024%.
Which hedge fund is a major shareholder of AlzeCure Pharma AB?
Currently, no hedge funds are holding shares in DE:AC6
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
AlzeCure Pharma AB
AlzeCure Pharma AB (publ) is a pharmaceutical firm focused on pioneering drug treatments for debilitating conditions impacting the central nervous system (CNS). The company's pipeline of potential medicines is rooted in three distinct research platforms: NeuroRestore, Alzstatin, and Painless. Among its experimental compounds, ACD856 is currently in Phase I clinical trials for multiple indications, including Alzheimer's disease, sleep disturbances, traumatic brain injuries, and Parkinson's disease. Furthermore, ACD857, ACD679, and ACD680 are being developed for Alzheimer's treatment. Another candidate, ACD440, a TRPV1 antagonist intended for neuropathic pain, has successfully completed its Phase I clinical assessment. Additionally, TrkA-NAM is in development to alleviate osteoarthritic pain. Founded in 2012, AlzeCure Pharma AB (publ) maintains its headquarters in Huddinge, Sweden.